ArticleDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2026
Variability in time to surveillance endoscopy for eosinophilic esophagitis remission and relation to treatment outcomes.
Article in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Patients with eosinophilic esophagitis (EoE) in remission require monitoring, but optimal timing for endoscopic assessment is unknown. We aimed to assess variability in time from remission to surveillance endoscopy and associations with disease outcomes. This retrospective cohort study included patients with EoE who achieved histologic remission (<15 eos/hpf) while on stable treatment and had at least one surveillance endoscopy with biopsy after remission. Time to surveillance was categorized (≤1 year, 1-2 years, >2 years) and compared to a range of EoE clinicopathologic characteristics and disease outcomes. The 91-patient cohort had substantial variability in time to first surveillance endoscopy (mean 1.3 ± 1.0 years; median/IQR 1.0/0.6-1.8; range 0.2-7.3). While most patient characteristics were not associated with time to surveillance, larger dilation size at remission correlated with longer surveillance intervals (R = 0.36, p = 0.03), and EoE Endoscopic Reference Score (EREFS) was inversely associated (R = -0.21, p = 0.07). Outcomes of EREFS, Index of Severity of EoE, and eosinophil count were similar for <1, 1-2, or 2+ years surveillance intervals. However, numerically fewer patients with endoscopy 2+ years after remission maintained histologic response (59% vs. 78% at ≤1 year and 82% at 1-2 years; p = 0.15) and had more ongoing EoE symptoms (47% vs. 34% at ≤1 year and 24% at 1-2 years; p = 0.26). Surveillance timing in EoE remission varies widely and is largely unexplained by clinical features, except for dilation size. While outcomes were similar across intervals, patients with longer surveillance (>2 years) had numerically less histologic response and more persistent symptoms, warranting further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.